Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • Viral NS3/NS4A serine protease is essential for HCV replication and evasion of immune responses[Scheel 2013; Horner 2013]
  • 4 NS3/NS4A protease inhibitors are approved and marketed in the United States and European Union: glecaprevir, grazoprevir, paritaprevir, and voxilaprevir
    • The protease inhibitors boceprevir, simeprevir, and telaprevir are no longer marketed
  • Paritaprevir
      Grazoprevir
        Voxilaprevir
          Glecaprevir

          Action required